Exploring Purple Biotech Ltd. (PPBT) Investor Profile: Who’s Buying and Why?

Are you tracking Purple Biotech Ltd. (PPBT) and wondering who's investing and why? As of April 2025, understanding the investor profile of PPBT can provide valuable insights. Recent data shows that institutional investors hold a significant number of shares, with Kingswood Wealth Advisors, LLC holding 33,594 shares and Two Sigma Securities, LLC holding 15,374 shares as of December 31, 2024. Furthermore, Purple Biotech announced promising financial results for 2024, including a 79% reduction in death risk for biomarker-selected patients in the CM24 Phase 2 pancreatic cancer trial. With $8.2 million in cash and equivalents as of December 31, 2024, and a registered direct offering that raised $2.8 million, who is betting on Purple Biotech and what do they see in the company's future?

Purple Biotech Ltd. (PPBT) Who Invests in Purple Biotech Ltd. (PPBT) and Why?

Understanding the investor profile of Purple Biotech Ltd. (PPBT) provides valuable insights into the market's perception of the company. By examining the types of investors, their motivations, and typical investment strategies, a clearer picture emerges of what drives interest in this clinical-stage biopharmaceutical company.

Key Investor Types:

The investor base of Purple Biotech Ltd. (PPBT) includes a mix of retail and institutional investors. Institutional investors, such as hedge funds and wealth advisors, often hold a significant portion of the company's shares. According to recent filings, Purple Biotech Ltd. (PPBT) has 13 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 80,353 shares.

• Retail Investors: Individual investors who buy and sell shares for their own accounts.
• Institutional Investors: Entities that invest on behalf of others, including:
• Hedge Funds: Actively managed funds that may employ various strategies to generate returns.
• Wealth Advisors: Financial professionals who manage investments for high-net-worth individuals and families.

Largest shareholders include:

• Kingswood Wealth Advisors, Llc
• Two Sigma Securities, Llc
• UBS Group AG
• Group One Trading, L.p.
• Bnp Paribas Arbitrage, Sa
• Morgan Stanley
• Rhumbline Advisers
• Tower Research Capital LLC (TRC)
• TD Waterhouse Canada Inc.
• SBI Securities Co., Ltd.

Investment Motivations:

Investors are attracted to Purple Biotech Ltd. (PPBT) for several reasons, primarily related to its potential growth and market position within the biopharmaceutical industry.

• Growth Prospects: Purple Biotech Ltd. (PPBT) is focused on developing innovative therapies to overcome tumor immune evasion and drug resistance. Its oncology pipeline includes CM24, NT219 and IM1240, each targeting different aspects of cancer treatment. Positive developments, such as clinical trial successes, can drive investor enthusiasm.
• Market Position: As a clinical-stage company committed to developing first-in-class therapies, Purple Biotech Ltd. (PPBT) aims to improve treatment outcomes for cancer patients.

Investment Strategies:

The investment strategies employed by Purple Biotech Ltd. (PPBT) investors can vary widely depending on their investment goals and risk tolerance.

• Long-Term Holding: Some institutional investors may adopt a long-term holding strategy, maintaining their positions for extended periods to benefit from the company's potential growth.
• Short-Term Trading: Other investors, particularly hedge funds, may engage in short-term trading strategies to capitalize on price fluctuations and market events.

Institutional Ownership Details:

Institutional ownership in Purple Biotech Ltd. (PPBT) reflects the current positions held by institutions and funds, along with recent changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. Schedule 13D indicates that the investor holds (or held) more than 5% of the company and intends (or intended) to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%.

As of April 17, 2025, the share price was $2.84 per share. Previously, on April 18, 2024, the share price was $9.22 per share, representing a decline of 69.20% over that period.

Here's a summary of some major shareholders as of December 31, 2024:

For more information about Purple Biotech Ltd. (PPBT), you can explore their Mission Statement, Vision, & Core Values of Purple Biotech Ltd. (PPBT).

Purple Biotech Ltd. (PPBT) Institutional Ownership and Major Shareholders of Purple Biotech Ltd. (PPBT)

Institutional investors and major shareholders can significantly influence a company like Purple Biotech Ltd. (PPBT). Their investment decisions can impact the company's stock price, strategic direction, and overall market perception. Understanding the ownership structure provides insights into the stability and potential future performance of the company.

Unfortunately, as of my knowledge cutoff in April 2025 and based on the latest search results, comprehensive, up-to-date details regarding the top institutional investors and their exact shareholdings in Purple Biotech Ltd. (PPBT) for the 2024 fiscal year are not available. Real-time updates on institutional ownership often require specialized financial data subscriptions.

To find the most current information, consider exploring these resources:

• Financial Data Providers: Services like Bloomberg Terminal, Thomson Reuters Eikon, and FactSet provide detailed ownership data, including institutional holdings and recent changes.
• SEC Filings: Check Purple Biotech Ltd. (PPBT)'s filings with the Securities and Exchange Commission (SEC), particularly 13F filings, which disclose the holdings of institutional investment managers with over $100 million in assets under management.
• Investor Relations: Visit the investor relations section of Purple Biotech Ltd. (PPBT)'s website for potential updates and disclosures on major shareholders.

Without specific current data, I can offer a general perspective on how to interpret institutional ownership information:

Changes in Ownership:

• Increased Stakes: If institutional investors are increasing their positions, it could signal confidence in the company's future prospects.
• Decreased Stakes: Conversely, a decrease in institutional ownership might indicate concerns about the company's performance or outlook.

Impact of Institutional Investors:

• Stock Price: Large institutional investors can drive significant trading volume, influencing the stock price.
• Company Strategy: Major shareholders may engage with the company's management to influence strategic decisions.

For more insights into Purple Biotech Ltd. (PPBT), you might find this resource helpful: Purple Biotech Ltd. (PPBT): History, Ownership, Mission, How It Works & Makes Money

Purple Biotech Ltd. (PPBT) Key Investors and Their Impact on Purple Biotech Ltd. (PPBT)

Understanding who invests in Purple Biotech Ltd. (PPBT) and why can offer valuable insights into the company’s potential and market sentiment. Examining the profiles and recent activities of key investors can reveal their influence on company decisions and stock performance.

While comprehensive, real-time data on all investors may not be readily available, focusing on institutional ownership and significant stakeholders can provide a clear picture. Recent moves, such as major stake acquisitions or divestments, and any activist involvement are crucial to monitor.

Key aspects to consider include:

• Notable Investors: Identifying prominent funds, activist investors, or influential individuals holding significant stakes in Purple Biotech Ltd. (PPBT).
• Investor Influence: Assessing how these investors impact company strategies, decisions, and overall stock movements.
• Recent Moves: Tracking recent buying or selling activities by major investors, as well as any public activist campaigns or strategic proposals.

Institutional investors often hold substantial shares in publicly traded companies like Purple Biotech Ltd. (PPBT). These institutions conduct thorough research before investing, and their actions can significantly influence stock prices. Monitoring their holdings can provide insights into the perceived value and future prospects of the company.

Activist investors can also play a pivotal role. These investors often seek to influence company management and strategy to unlock value. Their involvement can lead to significant changes in company direction and, consequently, stock performance.

To stay informed about investor activity, it's essential to monitor SEC filings, such as 13D and 13G filings, which disclose significant ownership positions. Tracking these filings can provide early warnings of potential shifts in investor sentiment and company strategy.

For further insights into Purple Biotech Ltd. (PPBT)’s financial standing, see: Breaking Down Purple Biotech Ltd. (PPBT) Financial Health: Key Insights for Investors

Purple Biotech Ltd. (PPBT) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions is crucial for evaluating the potential of Purple Biotech Ltd. (PPBT). Several factors influence how investors perceive the company, including major shareholder activity, market trends, and analyst ratings.

Investor Sentiment:

Currently, institutional ownership in Purple Biotech Ltd. (PPBT) is relatively low. According to Fintel, as of April 17, 2025, 13 institutional owners and shareholders have filed 13D/G or 13F forms with the Securities and Exchange Commission (SEC), holding a total of 80,353 shares. Major shareholders include:

• Kingswood Wealth Advisors, Llc
• Two Sigma Securities, Llc
• UBS Group AG
• Group One Trading, L.p.
• Bnp Paribas Arbitrage, Sa
• Morgan Stanley
• Rhumbline Advisers
• Tower Research Capital LLC (TRC)
• TD Waterhouse Canada Inc.
• SBI Securities Co., Ltd.

WallStreetZen indicates that as of 2025, institutional shareholders own approximately 0.02% of Purple Biotech, insiders hold 0.00%, and retail investors account for the remaining 99.98%. Kingswood Wealth Advisors LLC is the largest individual shareholder, owning 33,594.00 shares valued at $91.54k.

The put/call ratio can be used to gauge investor sentiment, particularly among actively-managed funds. A high put/call ratio suggests a bearish sentiment, while a low ratio indicates a bullish outlook.

Recent data indicates a mixed sentiment among investors. INDmoney reported a -67% decrease in search interest for Purple Biotech stock from India in the last 30 days, suggesting a downward trend in interest.

Recent Market Reactions:

Purple Biotech's stock price has experienced significant volatility. On April 17, 2025, the share price was $2.84. However, on April 18, 2024, the price was $9.22, representing a 69.20% decline over the year. The stock's 52-week high is $20.60, while the 52-week low is $2.00, highlighting the wide range of price fluctuations.

According to StockInvest.us, Purple Biotech Ltd. stock gained 13.15% on April 17, 2025, rising from $2.51 to $2.84. The stock fluctuated 11.81% during that day, with a low of $2.54 and a high of $2.84. This indicates high volatility and potential for both gains and losses.

News from December 2024 showed significant positive movement, with the stock trading up by 55.53% following positive developments in pancreatic cancer treatment and promising Q3 earnings.

Analyst Perspectives:

Analyst ratings for Purple Biotech vary. TipRanks reports a consensus rating of 'Moderate Buy' based on ratings from Wall Street analysts. The average price target is $33.00, which represents a significant 1214.74% increase from the current price of $2.51. However, it's important to note that this is based on a limited number of analysts.

Jones Trading analyst Catherine Novack lowered the price target on Purple Biotech Ltd. to $3.00 from $8.00 but maintained a 'Buy' rating, reflecting a cautiously optimistic outlook.

Macroaxis reports a consensus 'Buy' recommendation but advises caution, noting that the number of analysts providing opinions may be insufficient for a strong consensus. The projected target price consensus is $33.00, but this should be validated with individual analysis.

Additional Factors:

Several recent developments could influence investor sentiment:

• NT219 Phase 2 Trial: Purple Biotech is advancing NT219 into a Phase 2 trial for head and neck cancer, which could be a significant breakthrough.
• Registered Direct Offering: The company closed a $2.8 million registered direct offering, indicating investor confidence and providing funds for research and development.
• CM24 Study Results: Final results from a Phase 2 study of CM24 targeting pancreatic ductal adenocarcinoma (PDAC) could influence stock performance.

Technical analysis from TipRanks indicates a negative sentiment, with the price below the 50, 100, and 200-day moving averages. However, the Relative Strength Index (RSI) is neutral at 40.58, and the Stochastic Oscillator is positive at 13.01.

For a deeper dive into the company's background, explore Purple Biotech Ltd. (PPBT): History, Ownership, Mission, How It Works & Makes Money.